Hjem › Tripelnegativ brystkreft › California › San Francisco
Kliniske studier for Tripelnegativ brystkreft i San Francisco, CA
11 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt San Francisco (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekruttererFase 3
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016), San Francisco
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekruttererFase 3
- Kaiser Permanente - San Francisco ( Site 0080), San Francisco
Intratumoral N17350 in Advanced Solid Tumors
RekruttererFase 1/2
- University of California, San Francisco, San Francisco
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- City of Hope (Duarte), San Francisco
- UCSF Medical Center, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
RekruttererFase 2
- University of California, San Francisco, San Francisco
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruttererFase 2
- University of California San Francisco (UCSF), San Francisco
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
RekruttererFase 2
- University of California San Francisco, San Francisco
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- University of California, San Francisco, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
RekruttererFase 1
- University of California, San Francisco, San Francisco
A Multicenter Cancer Biospecimen Collection Study
RekruttererObservasjonsstudie
- Curebase, San Francisco
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andre studier i San Francisco
- Prostatakreft45 studier
- Brystkreft43 studier
- Ikke-småcellet lungekreft36 studier
- Kreft (alle typer)35 studier
- Hjertesvikt29 studier
- Metastatisk kreft28 studier
- Lungekreft22 studier
- Melanom22 studier
- Pankreaskreft20 studier
- Eggstokkreft19 studier
- Kolorektal kreft18 studier
- Kardiovaskulær sykdom18 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.